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The combination of unsaponiﬁable oil extracted from avocado and soy-
beans has been investigated over the last decade with promising results
in experimental animal models and human patients but blinded controlled
studies in a target species such as the horse are lacking. The purpose
of this study was to evaluate ASU compared to placebo treatment in an
equine model of OA.
Methods: This study was a blinded experimentally controlled randomized
block design that utilized 16 horses in an established model of osteoarthri-
tis. On day 0 of the study, arthroscopic surgery was performed, and OA
was induced unilaterally in the mid-carpal joint of all horses. Also on
day 0, horses were divided into two treatment groups: placebo control
and ASU treated. The placebo control horses (n = 8) received molasses
orally once daily, while the ASU treated horses (n = 8) received 6g of ASU
plus a similar volume of molasses orally, both treatments were continued
throughout the study period.
On day 14 horses began and continued treadmill exercise for the re-
maining 8 weeks of the study. Synovial ﬂuid and serum were assessed
every other week for total protein concentration, white blood cell count
(WBC) and levels of the inﬂammatory marker, prostaglandin E2 (PGE2).
Horses were assessed for lameness using the AAEP grading scale every
two weeks. At the termination of the study, operated joints were evaluated
grossly, and tissues were harvested for biochemical and routine histologic
examinations.
Results: All horses completed the study and no adverse events were
recorded. At the termination of the study horses treated with ASU were
observed to have signiﬁcantly improved total gross examination score
(articular cartilage erosion + synovial membrane hemorrhage score) in
their OA joint when compared to placebo treated horses. The degree of
lameness and other outcome parameters were not signiﬁcantly different
when ASU and Placebo treatments were compared although numerically
they appeared improved.
Conclusions: While the signiﬁcant improvements were modest, it is
more than has been seen with some other parenteral (Polysulfated
glycosaminoglycan and intravenous hyaluronan) and oral (hyaluronan)
products tested using the same model of equine OA. These data suggest
further research both using in vitro and clinical trials should be undertaken
to evaluate ASU.
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Purpose: Joint disease and speciﬁcally osteoarthritis (OA) is one of
the most prevalent and debilitating diseases affecting both humans and
horses. While claims that adipose derived stem cells improve horses
with clinical OA, no controlled clinical studies have been published in
horses or humans to date. Furthermore no controlled studies have been
published on bone marrow derived stem cells for the treatment of OA in
either humans or horse OA. Bone marrow derived stem cells expanded
in culture have been used to regenerate and/or repair a variety of tissues
but to date only one study has been published evaluating the in vivo
effects of intraarticular stem cell injection on decreasing the progression
of experimental OA in a goat model of OA This study used a medial
meniscectomy and cranial cruciate transection model to induce OA. The
decrease in OA seen in the study was thought to be secondary to the
regeneration of the medial meniscal tissues, which was dramatic in 7
of 9 cases. The design of the study did not lend itself to determining if
the stem cells had a direct effect on the articular cartilage. Based on
unpublished data there is some evidence that stem cells have a tropism
for ﬁbrillated articular cartilage. This coupled with the overwhelming
capacity of stem cells for regeneration of many tissue types, the current
study was undertaken. Unlike the study by Murphy et al., the model used
in the current study does not rely on joint instability (medial meniscal
model) to create secondary OA but rather an osteochondral fragment in
concert with articular cartilage and bone debris created at the time of
fragmentation. It is believed that the progression of OA in this model is
largely enzymatically and particle mediated.
Methods: This study was a blinded experimentally controlled random-
ized block design that utilized 24 horses in an established model of
osteoarthritis. On day 0 of the study, bilateral mid-carpal arthroscopic
surgery was performed, and OA was induced unilaterally in one mid-
carpal joint of all horses. On day 14 horses received either Placebo,
bone derived culture expanded stem cells (BDMSC) or adipose derived
stromal-vascular fraction (ADSVF). Also on day 14 the horses began a
strenuous exercise regime 5 days per week for the remaining 8 weeks
of the study. Pivotal parameters assessed included clinical pain, radio-
graphic and gross examinations as well as articular cartilage and synovial
membrane morphology and synovial ﬂuid prostaglandin E2 (PGE2).
Statistical analysis utilized both a Mixed model analysis of variance and
a Least Square mean when individual comparisons were made, and
p-values <0.05 were considered signiﬁcant.
Results: All horses completed the study and no adverse events were
recorded. Horses receiving Placebo treatment in the OA joint had a
signiﬁcant increase in all of the pivotal parameters. Neither horses re-
ceiving BDMSC or ADSVF in their OA joints showed any signiﬁcant
improvement in any of the same pivotal parameters except PGE2 which
was signiﬁcantly decreased in BDMSC treated horses.
Conclusions: The results of the current study and Murphy et al. com-
bined suggest that the regeneration of the medial meniscus in Murphy
et al.’s study may have in fact been the reason for less OA progression.
Furthermore, the current study also suggests that MSC’s by themselves
do little to counteract the progression of OA mediated by enzymatic
degradation and joint debris except for decreasing PGE2. It would appear
modiﬁcation of the MSC’s is needed if they are to be clinically useful in
treating the OA represented in the current model.
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Purpose: Interleukin-1 (Il-1) is thought to be the major mediator of joint
disease. Studies in both humans and horses have evaluated the use of a
natural antagonist (interleukin-1 receptor antagonist, Il-1Ra) to block Il-1
activity and decrease the progression of joint disease.
A novel product to the United States has been introduced for the treatment
of equine OA, autologous conditioned serum (ACS). This product has
been shown to stimulate the production of Il-1Ra from cultured peripheral
blood of human patients by 140 fold. The purpose of this study was to
evaluate ACS compared to placebo treatment using a horse model of OA.
Methods: This study was a randomized blinded controlled study that
utilized 16 horses in an established model of osteoarthritis. On day 0
of the study, arthroscopic surgery was performed, and OA was induced
unilaterally in the mid-carpal joint of all horses. On day 14, horses were
divided into two treatment groups: placebo control and ACS treated. The
placebo control horses had 6ml of saline injected into the OA joint on days
14, 21, 28 & 35 while the ACS treated joints (OA joints) received 6ml of
serum prepared as directed by the manufacturer at similar time periods.
On day 14 the horses began a strenuous exercise regime 5 days per week
for the remaining 8 weeks of the study. Synovial ﬂuid and serum were
assessed every other week for total protein concentration, white blood
cell count (WBC) and levels of the inﬂammatory marker, prostaglandin
E2 (PGE2). Horses were assessed for pain using a standardized scale
every two weeks. At the termination of the study, operated joints were
evaluated grossly, and tissues were harvested for biochemical and routine
histologic examinations.
Statistical analysis utilized an analysis of variance and a Least Square
mean for individual comparisons, p-values <0.05 were considered signif-
icant.
Results: All horses completed the study and no adverse events. ACS
processed serum had a signiﬁcant increase in Il-1Ra concentrations when
compared to control serum (234±27 versus 45±29 pg/mL, respectively).
Horses treated with ACS were observed to have signiﬁcantly improved
lameness in OA joints, even ﬁve weeks after the last treatment when
compared to placebo treated horses (1.3±0.2 versus 2.1±0.2, respec-
tively). A signiﬁcant reduction in synovial membrane hyperplasia was also
seen in the treated compared to placebo OA joints at day 70 (0.4±0.3
versus 1.3±0.3, respectively). The levels of IL1-Ra were also signiﬁcantly
elevated in the joints of ACS treated horses after day 35 and were
estimated to be 71±13 versus 44±13 pg/mL on day 70 when treated
versus placebo synovial ﬂuid was compared respectively.
Conclusions: The ACS system used here stimulates peripheral white
blood cells to produce an “anti-inﬂammatory soup”. An import ﬁnding of
this study was no negative side effects associated with the intraarticular
administration of ACS. Signiﬁcant clinical improvement was seen following
treatment of induced OA at the last point measured during the study. Sig-
niﬁcant improvement was also noted in synovial membrane parameters,
as well as trends for gross improvement, further supporting a therapeutic
